Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review

References

• Coronavirus Resource Center. COVID-19 dashboard; 2021 [cited 2021 Sep 19]. Available from: https://coronavirus.jhu.edu/map.html?fbclid=IwAR3YAUh1zt-Y0G1gUqLxBypXPQuI1PzhQItISdwOYNgRR0om-BjGOv6Ya-0
   Google Scholar
• Koyama T, Weeraratne D, Snowdon JL, et al. Emergence of drift variants that may affect COVID-19 vaccine development. Pathogens. 2020;2020:1–7.
   Google Scholar
• Albano PM, Notarte KI, Macaranas I, et al. Cross-contamination in molecular diagnostic laboratories in low- and middle-income countries: a challenge to COVID-19 testing. PJP. 2020;5(2):7–11.
   Google Scholar
• Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med. 2020;8(11):693.
   PubMed Web of Science ®Google Scholar
• Dolgin E. How COVID unlocked the power of mRNA. Nature. 2021;589(7841):189–191.
   PubMed Web of Science ®Google Scholar
• Ríos S, Mas Romero M, Cortés Zamora EB, et al. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. J Am Geriatr Soc. 2021;69(6):1441–1447.
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–1306.
   PubMed Web of Science ®Google Scholar
• Tove H, Nissen K, Krambrich J, et al. Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. Infect Ecol Epidemiol. 2020;10(1):1754538.
   PubMedGoogle Scholar
• Liu X, Wang J, Xu X, et al. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1269–1274.
   PubMed Web of Science ®Google Scholar
• Jabal KA, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance. 2021;26(6):2100096.
   Web of Science ®Google Scholar
• Naaber P, Jürjenson V, Ainika Adamson S, et al. Antibody response after COVID-19 mRNA vaccination in relation to age, sex, and side effects. medRxiv. 2021.
   Google Scholar
• Salvagno GL, Henry BM, Di Piazza G, et al. Anti-SARS-Cov-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination. Diagnostics. 2021;11(5):832.
   Web of Science ®Google Scholar
• Pellini R, Venuti A, Pimpinelli F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021;36:100928.
   PubMedGoogle Scholar
• Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the BioNTech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis. 2021;73(11):2065–2072.
   PubMed Web of Science ®Google Scholar
• Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250.
   PubMed Web of Science ®Google Scholar
• Kelsen SG, Braverman AS, Aksoy MO, et al. A longitudinal study of BNT162b2 vaccine-induced humoral response and reactogenicity in health care workers with prior COVID-19 disease. medRxiv. 2021;21253845.
   Google Scholar
• Callegaro A, Borleri D, Farina C, et al. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. J Med Virol. 2021;93(7):4612–4615.
   PubMed Web of Science ®Google Scholar
• Efrati S, Catalogna M, Abu Hamad R, et al. Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations. Sci Rep. 2021;11(1):1–13.
   PubMed Web of Science ®Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981–984.
   PubMed Web of Science ®Google Scholar
• Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-Cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397(10280):1178–1181.
   PubMed Web of Science ®Google Scholar
• Padoan A, Dall'Olmo L, Rocca FD, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60–63.
   PubMed Web of Science ®Google Scholar
• Favresse J, Bayart J-L, Mullier F, et al. Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021;27(9):1351.e5–1351.e7.
   Web of Science ®Google Scholar
• Sasso BL, Giglio RV, Vidali M, et al. Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine. Diagnostics. 2021;11(7):1135.
   Web of Science ®Google Scholar
• Modenese A, Paduano S, Bargellini A, et al. Neutralizing anti-SARS-CoV-2 antibody titer and reported adverse effects, in a sample of Italian nursing home personnel after two doses of the BNT162b2 vaccine administered four weeks Apart. Vaccines. 2021;9(6):652.
   Web of Science ®Google Scholar
• Jahn M, Korth J, Dorsch O, et al. Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis. Vaccines. 2021;9(4):360–368.
   Web of Science ®Google Scholar
• Goupil R, Benlarbi M, Beaubien-Souligny W, et al. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. CMAJ. 2021;193(22):E793–E800.
   PubMed Web of Science ®Google Scholar
• Frantzen L, Cavaillé G, Thibeaut S, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort. Nephrol Dial Transplant. 2021;36(9):1756–1757.
   PubMed Web of Science ®Google Scholar
• Zitt E, Davidovic T, Schimpf J, et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients. Front Immunol. 2021;12(1):704773.
   PubMedGoogle Scholar
• Torreggiani M, Blanchi S, Fois A, et al. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021;99(6):1494–1496.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173.
   PubMed Web of Science ®Google Scholar
• Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14(1):1–12.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133.
   PubMed Web of Science ®Google Scholar
• Goshen-Lago T, Waldhorn I, Holland R, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507.
   PubMed Web of Science ®Google Scholar
• Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–1339.
   PubMed Web of Science ®Google Scholar
• Gallo A, Capuano R, Donnarumma G, et al. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. Neurol Sci. 2021;42(9):3523–3526.
   PubMed Web of Science ®Google Scholar
• Korth J, Jahn M, Dorsch O, et al. Impaired humoral response in renal transplant recipients to Sars-Cov-2 vaccination with Bnt162b2 (Pfizer-BioNTech). Viruses. 2021;13(5):756–759.
   PubMed Web of Science ®Google Scholar
• Marinaki S, Adamopoulos S, Degiannis D, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. Am J Transplant. 2021;21(8):2913–2915.
   PubMed Web of Science ®Google Scholar
• Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir Med. 2021;9(6):e52–e53.
   PubMed Web of Science ®Google Scholar
• Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719–2726.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2021;38(1):e3465.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;13:1–10.
   Google Scholar
• Vassilaki N, Gargalionis AN, Bletsa A, et al. Impact of age and sex on antibody response following the second dose of COVID-19 BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms. 2021;9(8):1725.
   PubMed Web of Science ®Google Scholar
• Butt A, Omer SB, Yan P, et al. SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting. Ann Intern Med. 2021;174(10):1404–1408.
   PubMed Web of Science ®Google Scholar
• Danthu C, Hantz S, Dahlem A, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32(9):2153–2158.
   PubMed Web of Science ®Google Scholar
• Lord JM. The effect of ageing of the immune system on vaccination responses. Hum Vaccin Immunother. 2013;9(6):1364–1367.
   PubMed Web of Science ®Google Scholar
• Allen JC, Toapanta FR, Chen W, et al. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine. 2020;38(52):8264–8272.
   PubMed Web of Science ®Google Scholar
• Olafsdottir TA, Alexandersson KF, Sveinbjornsson G, et al. Age and influenza-specific pre-vaccination antibodies strongly affect influenza vaccine responses in the Icelandic population whereas disease and medication have small effects. Front Immunol. 2017;8:1872.
   PubMed Web of Science ®Google Scholar
• Haralambieva IH, Painter SD, Kennedy RB, et al. The impact of immunosenescence on humoral immune response variation after influenza a/H1N1 vaccination in older subjects. PLOS One. 2015;10(3):e0122282.
   PubMed Web of Science ®Google Scholar
• Bartleson JM, Radenkovic D, Covarrubias AJ, et al. SARS-CoV-2, COVID-19 and the ageing immune system. Nat Aging. 2021;1(9):769–782.
   PubMedGoogle Scholar
• Giefing-Kröll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309–321.
   PubMed Web of Science ®Google Scholar
• Fischinger S, Boudreau CM, Butler AL, et al. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239–249.
   PubMed Web of Science ®Google Scholar
• Ciarambino T, Para O, Giordano M, et al. Immune system and COVID-19 by sex differences and age. Womens Health. 2021;17:17455065211022262.
   Google Scholar
• Ma Q, Hao ZW, Wang YF. The effect of estrogen in coronavirus disease 2019. Am J Physiol Lung Cell Mol Physiol. 2021;321(1):219–227.
   Web of Science ®Google Scholar
• Manica M, Pancheri S, Poletti P, et al. Risk of symptomatic infection during a second coronavirus disease 2019 wave in severe acute respiratory syndrome coronavirus 2-seropositive individuals. Clin Infect Dis. 2021;2019–2022.
   Google Scholar
• Fraley E, LeMaster C, Geanes E, et al. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Med. 2021;19(1):1–12.
   PubMed Web of Science ®Google Scholar
• Demonbreun AR, Sancilio A, Velez ME, et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected persons. medRxiv. 2020;6(165):1–13.
   Google Scholar
• Krammer F, Srivastava K, Team P, et al. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. medRxiv. 2021;21250653.
   Google Scholar
• Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9(12):737–746.
   PubMed Web of Science ®Google Scholar
• Kwetkat A, Heppner HJ. Comorbidities in the elderly and their possible influence on vaccine response. Interdiscip Top Gerontol Geriatr. 2020;43:73–85.
   PubMedGoogle Scholar
• Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049–2055.
   PubMed Web of Science ®Google Scholar
• Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526–1533.
   PubMed Web of Science ®Google Scholar
• Windpessl M, Bruchfeld A, Anders HJ, et al. COVID-19 vaccines and kidney disease. Nat Rev Nephrol. 2021;17(5):291–293.
   PubMed Web of Science ®Google Scholar
• Mulley WR, Dendle C, Ling JEH, et al. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant. 2018;37(7):844–852.
   PubMed Web of Science ®Google Scholar
• Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011;11(8):1727–1733.
   PubMed Web of Science ®Google Scholar
• Schaffer SA, Husain S, Delgado DH, et al. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am J Transplant. 2011;11(12):2751–2754.
   PubMed Web of Science ®Google Scholar
• Danziger-Isakov L, Cherkassky L, Siegel H, et al. Effects of influenza immunization on humoral and cellular alloreactivity in humans. Transplantation. 2013;89(7):838–844.
   Google Scholar
• Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11(10):2020–2030.
   PubMed Web of Science ®Google Scholar
• Aslam S, Goldstein DR, Vos R, et al. COVID-19 vaccination in our transplant recipients: the time is now. J Heart Lung Transplant. 2021;40(3):169–171.
   PubMed Web of Science ®Google Scholar
• Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20(7):1800–1808.
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–359.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284.
   PubMed Web of Science ®Google Scholar
• Looi CK, Chung FFL, Leong CO, et al. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019;38(1):1–23.
   PubMed Web of Science ®Google Scholar
• Esperança-Martins M, Gonçalves L, Soares-Pinho I, et al. Humoral immune response of SARS-CoV-2-infected patients with cancer: influencing factors and mechanisms. Oncologist. 2021;26(9):e1619–e1632.
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, de Weerdt O, van der Velden AMT, et al. Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Ann Oncol. 2011;22(9):2031–2035.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278(4):369–395.
   PubMed Web of Science ®Google Scholar
• Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis. 2016;3(4):151–155.
   Google Scholar
• Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. 2016;7(1):66–75.
   PubMed Web of Science ®Google Scholar
• Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes. 2012;36(8):1072–1077.
   PubMed Web of Science ®Google Scholar
• Francisco V, Pino J, Campos-Cabaleiro V, et al. Obesity, fat mass and immune system: role for leptin. Front Physiol. 2018;9:640–620.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Itoh H. Hypertension as a metabolic disorder and the novel role of the gut. Curr Hypertens Rep. 2019;21(8):63.
   PubMed Web of Science ®Google Scholar
• Singh MV, Chapleau MW, Harwani SC, et al. The immune system and hypertension. Immunol Res. 2014;59(1–3):243–253.
   PubMed Web of Science ®Google Scholar
• Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398(10304):981–990.
   PubMed Web of Science ®Google Scholar
• Bensouna I, Caudwell V, Kubab S, et al. SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis. Am J Kidney Dis. 2021;79(2):185–192.e1.
   PubMed Web of Science ®Google Scholar
• Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27(11):2025–2031.
   PubMed Web of Science ®Google Scholar
• Notarte KI, Guerrero-Arguero I, Velasco JV, et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a rapid systematic review. medRxiv. 2021.
   Google Scholar
• Lippi G, Henry BM, Plebani M. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role? Clin Chem Lab Med. 2021;59(12):1885–1888.
   PubMed Web of Science ®Google Scholar